Background: Wilms' tumor 1 is a tumor suppressor gene. The gene is located in chromosome 11p13. And its expression was found in many solid tumors (including ovarian tumor) and also expressed in hematologic malignancies, Recent studies found that WT1 to be involved in angiogenesis. Objectives: To evaluate the expression of WT1 in surface epithelial ovarian tumorand study the possibility of using WT1 as replacement of both;ovarian tumor marker CA125 and a endothelial cell phenotypic marker CD34.
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Introduction:
Ovarian cancer is the second leading cause of cancer-related death in women worldwide. Since most patients are diagnosed in advanced disease stages.1 In Iraq, ovarian tumors rank the 6th commonest cancer and constituted 3.81 % according to Iraqi Cancer Board Registry in 2009.2 These tumors comprise several distinct histological types. The surface epithelial tumors account for 60% of all ovarian neoplasm. 3 Its etiology is poorly understood . It's more common in nulliparous women, in those living in industrialized countries and epidemiological studies have shown a significant reduction in ovarian cancer in women who have used oral contraceptive pills. Most cases of epithelial ovarian cancer are sporadic, occurring with no family history of the disease.4Wilms' tumor 1 (WT1) is a transcription factor first found in Wilms' tumor of the kidney, where it acts as a tumor suppressor gene. The gene is located in chromosome 11p13. And WT1 was associated with cell proliferation in many solid tumors (malignant melanoma,5 breast cancer,6 glialtumors7 , desmoplastic small round cell tumors.8And epithelial ovarian tumors 9) .And also found in hematologic malignancies (myeloid leukemia cells)10 recent studies have reported correlations between WT1 and neovascularization in histogenetics , normal genitourinary development, cardiac malformation and tumor angiogenesis. 11 WT-1 is a useful
The role of Wilm's Tumor1 immunohistochemical marker in surface epithelial Muna I. AL Hafedh ovarian tumor marker for detection of ovarian tumor cells, 11and is also consistent with that of a recent study in 2008, which reported that "Endothelial WT-1 expression was detected in 95% of 113 tumors of different origin", 12 including expression of WT1 in endothelial cells in human breast tumors. Li HJ. , et al in 2009 assessed that WT-1 immunohistochemistry have dual usages in evaluation of the myoepithelial cells and micro-vessel density in breast cancer. 13As the human ovary is rich in blood vessels and WT-1 has been used as a biomarker for ovarian tumors11 Together, these findings suggest that a single WT1 immunohistochemistry have dual usages in evaluation of both ovarian tumor cells and the vascular density. 14 Single WT -1 immunohistochemistry can be used to assess both the tumor cells and micro-vascular density in ovarian tumors as Yi-Hsuan H. Et al in 2010 suggest that WT-1 is expressed in both tumor and endothelial cells in ovarian tumor.14 It is coexpressed with a well-defined ovarian tumor marker CA125 15 ,and also with a endothelial cell phenotypic marker CD34, in the same cells. Especially in serous tumor whereas in other surface epithelial tumors was with no benefit. 16
Patients and Methods :
This is a retrospective ( cross sectional ) study of ( 60 ) 
Results:
WT1 was observed as brown precipitation in the nuclei of surface epithelial tumor cells. WT1 was scored, and graded on a 0 to 3 scale :0 (negative), 1 (weak), 2 (medium) and 3 (strong) ; While the extent of staining was scored as : 0 (0 %) , 1 ( 1-25 % ) , 2 (26-50% ) , 3 (51-75% ) and 4 (76-100% ) The sum of the intensity and extent score was used as the final staining score (0-7) for WT1.17CD34was observed red-brown colored precipitate at the specific cytoplasmic site and cell membrane of CD34 antigen. Estimation of microvessel density(Weidner's method): slides were first scanned at 100× magnification, and five areas of maximum microvessels density (MVD) called hot spots were identified at 200× magnification on each slide. In each of these hot spots, microvessels (capillaries and small venules) were counted at 400×. In each case, means of the hot spots were counted.18 CA125 was observed a brown colored in the cell membrane of surface epithelial tumor cells. Intensity of CA125 was graded on a 0 to 3 scale ( 0 for no staining , + for weak ; ++ for moderate; and +++ for strong ). The percentage of cells was scored as follows : 1 for (0-25%) ; 2 for ( 26-50%) ; 3 for (51-75%) ; and 4 for (76-100%). The values of the staining intensity and the percent of immunoreactive cells were multiplied to obtain a composite score ranging from 0 to 12. 19 Statistical Analysis: Spss version 20 was used for data entry and analysis. Tests used : One -Way -Anova test, tukey B post -hoc test , Kruskall -Wallis test where P-value ≤ 0.05 was significant. Spearman rho correlation test where P -value ≤ 0.01 was significant.
A total of sixty female patients ; thirty cases were diagnosed as surface epithelial tumors of the ovary , an additional 30 patients with normal ovary were taken as a control study group.The mean age of the patients with malignant ovarian tumor was (49 ±13.5 ) years , and for the control group was (49.8 ± SD 6.7 ) years. The WT1 scores expression was highly significant in serous tumors than other cancer types. As shown in table (1) , figure (1) .
The role of Wilm's Tumor1 immunohistochemical marker in surface epithelial
Muna I. AL Hafedh ovarian tumor Assessing the differences in distribution of immunomarker expressions between malignant cases and control group :
•There was no significant difference in CD34-MVD expression between malignant and control group cases. ( p-value =0.5).
•There was no significant difference in WT1-MVD expression between malignant and control group cases. ( p-value = 0.8)
•There was significant difference in CA125 expression between malignant and control group cases. ( p-value < 0.001)
•There was significant difference in WT1 expression between malignant and control group.( p-value < 0.001).as seen in table (3), figure (4).
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Discussion:
Ovarian cancer is second most commonly diagnosed gynecological malignancy after endometrial cancer. 20 In Iraq, it is the sixth most common cancer among females, it constituted 3.81% according to Iraqi Cancer Board Registry in 2009. 2 Due to their nonspecific initial symptoms, 70% of patients have widespread metastatic disease at the time of diagnosis.21 Various recent immunohistochemical studies of ovarian cancer have suggested that expression of particular markers may help in predicting outcome , and therefore guide therapeutic choices. 22 the present study showed no significant correlation between patient age and degree of WT1 expression ) P -value . (0.9 = There is no previous or similar studies found for comparison , but a study on thyroid gland et al. 2002 ,30 Hecht JL. et al. 2002 , 31Goldestein N. et al. 2002 In the present study there is no statically significant of WT1-MVD expression between malignant and control group cases (P-value = 0.8) There is no previous and similar study could be found for comparison. Regarding CD34-MVD there is no difference between malignant and control group cases in our study(P-value = 0.5). And this agree with Yi-Hsuan H. 2010 , 14ES Bamberge 2002 , 37and Makoto et al 1997 And the similarlarity in MVDs in the benign and malignant tumors suggested that angiogenesis in ovarian tumors is responsible for tumor growth rather than malignant transformation. Regarding WT1 expression in malignant and control group cases there is no correlation) .P -value. (0.001 And this agreed with Yi-Hsuan H. 2010 study .14 Regarding
The role of Wilm's Tumor1 immunohistochemical marker in surface epithelial Muna I. AL Hafedh ovarian tumor the CA125 expression between malignant and control group cases in the present study showed marked correlation) Pvalue (0.001 and this agreed with Yi-Hsuan H. 2010 . 14 Author Contribution: Muna I. AL Hafedh : study conception ,design, practical part of IHC ,drafting of manuscript, interpretation of data and critical revision. Sahira A. Ali : interpretation of data, histopathological examination and critical revision. Lubab F. Talal: interpretation of data and critical revision.
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